title: Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial.
authors.forename: P
authors.initials: P
authors.lastname: Gionchetti
authors.forename: F
authors.initials: F
authors.lastname: Rizzello
authors.forename: A
authors.initials: A
authors.lastname: Ferrieri
authors.forename: A
authors.initials: A
authors.lastname: Venturi
authors.forename: C
authors.initials: C
authors.lastname: Brignola
authors.forename: M
authors.initials: M
authors.lastname: Ferretti
authors.forename: S
authors.initials: S
authors.lastname: Peruzzo
authors.forename: M
authors.initials: M
authors.lastname: Miglioli
authors.forename: M
authors.initials: M
authors.lastname: Campieri
mesh_terms: D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000378:metabolism; D004311:Double-Blind Method; D005765:Gastrointestinal Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D010865:Pilot Projects; D010919:Placebos; D012294:Rifamycins / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000078262:Rifaximin
chemical_list: D005765:Gastrointestinal Agents; D010919:Placebos; D012294:Rifamycins; D000078262:Rifaximin